144 related articles for article (PubMed ID: 11866308)
1. Pioglitazone-associated fulminant hepatic failure.
Chase MP; Yarze JC
Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
[No Abstract] [Full Text] [Related]
2. Diabetes drug Rezulin: take it, but take precautions.
Health News; 1999 May; 5(6):7. PubMed ID: 10546576
[No Abstract] [Full Text] [Related]
3. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
4. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
5. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
6. Diabetes medicine update. Old dogs, new tricks.
Nakamoto M
Diabetes Self Manag; 2003; 20(1):14-5. PubMed ID: 12632553
[No Abstract] [Full Text] [Related]
7. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
8. Accelerated hypertension due to rosiglitazone therapy.
Vikram NK; Misra A; Devi JR
Indian Heart J; 2002; 54(6):733. PubMed ID: 12674195
[No Abstract] [Full Text] [Related]
9. Troglitazone-associated hepatic failure.
Booth AM; Caldwell SH; Iezzoni JC
Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
[No Abstract] [Full Text] [Related]
10. [Type 2 diabetes. A new kind of insulin sensitizer at the door].
Böhm S
MMW Fortschr Med; 1999 Jul; 141(27):56-7. PubMed ID: 10904588
[No Abstract] [Full Text] [Related]
11. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
12. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
13. Upadate on oral treatments for type II diabetes.
Dykeman J
CANNT J; 2002; 12(1):41-2. PubMed ID: 11979652
[No Abstract] [Full Text] [Related]
14. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
15. Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
Buse JB
Am J Manag Care; 2000 Aug; 6(13 Suppl):S710-7. PubMed ID: 11183423
[No Abstract] [Full Text] [Related]
16. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
17. New labeling and use changes for Rezulin.
Klonoff DC
Diabetes Technol Ther; 1999; 1(3):350. PubMed ID: 11484719
[No Abstract] [Full Text] [Related]
18. Liver failure in a patient receiving rosiglitazone therapy.
Su DH; Lai MY; Wu HP
Diabet Med; 2006 Jan; 23(1):105-6. PubMed ID: 16409577
[No Abstract] [Full Text] [Related]
19. Pioglitazone: the future.
Brunetti P
Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
[No Abstract] [Full Text] [Related]
20. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
